ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

BioFluidica is Awarded NIH Grant Funding through the Midwest Biomedical Accelerator Research Consortium for an At-Home Device Using Breakthrough Technology in the Fight Against COVID-19

SAN DIEGO: SAN DIEGO, Aug. 12, 2021 /PRNewswire/ — BioFluidica, a privately held biotechnology company in conjunction with the University of Kansas, today announced they have been awarded a grant from the Midwest Biomedical Accelerator Research Consortium on behalf of the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx… Click here to view original post… […]

No Picture
News

Debut Biotech Raises $22.6M Series A to Commercialize High-Value Ingredients from Proprietary Cell-Free Biomanufacturing Platform

SAN DIEGO: SAN DIEGO, Aug. 12, 2021 /PRNewswire-PRWeb/ — Debut Biotech, a next generation biomanufacturing platform harnessing cell-free enzymes, today announced its $22.6M Series A financing, led by Material Impact. Participating investors include Cultivian Sandbox Ventures, Fine Structure Ventures, ACVC Ventures, Humboldt Fund, Cantos Ventures, as well as existing investors… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

SAN DIEGO: SAN DIEGO, Aug. 12, 2021 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian, will present at the Investor Summit Conference being… Click here to view original post… […]

No Picture
News

Viracta Therapeutics Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

SAN DIEGO: SAN DIEGO, Aug. 12, 2021 /PRNewswire/ — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced financial results for the second quarter of 2021 and provided clinical and corporate updates. "We entered the second half of the year with strong momentum thanks to… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial, Enabling Preparation of a BLA submission for Bentracimab for Reversal of Antiplatelet Effects of Ticagrelor

MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)—- $PHAS #TakeItToHeart–PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial Click here to view original post… […]

No Picture
News

Merck partner Artiva blueprints San Diego R&D, manufacturing site to take NK cell operation to the next level

In January, Artiva Biotherapeutics CEO Fred Aslan said his company is looking to create CAR-NK therapies with best-in-class efficacy made in a wholly owned manufacturing process. Artiva is now another step closer to that goal. Artiva will open a 52,000 square-foot headquarters in San Diego that will house its R&D and… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Neurelis Secures Senior Term Loan Facility Of Up To $150 Million From OrbiMed

SAN DIEGO: SAN DIEGO, Aug. 11, 2021 /PRNewswire/ — Neurelis, Inc., announced today that it has completed a senior term loan facility of up to $150 million from OrbiMed, one of the leading investors in the healthcare industry, to help fuel the company’s future growth. Craig C. Chambliss, President and… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

ChromaCode Adds Industry Leaders, Pat Balthrop and Kevin O’Boyle, to Board of Directors

CARLSBAD, Calif.–(BUSINESS WIRE)– #analysis–ChromaCode, Inc., a company that combines data science and proprietary reagents to improve clinical molecular analysis, today announced that Patrick Balthrop, Sr. and Kevin O’Boyle have joined the company’s Board of Directors. Mr. Balthrop is the former CEO and President of Luminex, a pioneer in multiplexed diagnostics… Click here to view original post… […]

No Picture
News

PYC Therapeutics to Host Quarterly Investor Call on August 17 at 9 a.m. AWST | 11 a.m. AEST

SAN DIEGO and PERTH, Australia: SAN DIEGO and PERTH, Australia, Aug. 11, 2021 /PRNewswire/ — PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited… Click here to view original post… […]

No Picture
News

Codex DNA Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 10, 2021 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2021. Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Regulus Therapeutics Reports Second Quarter 2021 Financial Results and Recent Updates

SAN DIEGO: SAN DIEGO, Aug. 10, 2021 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. "The… Click here to view original post… […]

No Picture
News

Janux Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, today reported financial results for the quarter ended June 30, 2021. “With the successful completions of a Series B financing and IPO this past quarter, we are… Click here to view original post… […]

No Picture
News

Keytruda keeps expanding with another priority review; Medicxi-backed eye drop maker wins new funding, regional deal

As Merck continues to chop away at a path to earlier lines of cancer treatment for Keytruda, the FDA is offering a hand. The agency has granted priority review for the PD-1 star as an adjuvant therapy in certain patients with renal cell carcinoma — which,… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Former Vice President, Regulatory Affairs at Abbott Rapid Diagnostics, Joins NDA Partners as Expert Consultant

ROCHELLE, Va.: ROCHELLE, Va., Aug. 10, 2021 /PRNewswire-PRWeb/ — NDA Partners President Earle Martin announced today that Leanne Kiviharju, a senior regulatory affairs executive with more than 20 years of experience leading regulatory operations in the in vitro diagnostic industry, has joined the firm as an Expert Consultant. Ms. Kiviharju’s… Click here to view original post… […]

No Picture
News

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today reported operating results for the second quarter ended June 30, 2021 and provided pipeline updates. Click here to view original post… […]

No Picture
News

Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain and COVID-19, announced today the availability of a presentation on its corporate website to provide an overview of Sorrento’s proprietary mRNA… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Inhibrx Reports Second Quarter 2021 Financial Results

SAN DIEGO: SAN DIEGO, Aug. 9, 2021 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, today reported financial results for the second quarter of 2021. Financial Results Cash and Cash Equivalents. As of June 30, 2021, Inhibrx had cash and cash equivalents of… Click here to view original post… […]


ADVERTISEMENT — Advertise With Biotech Networks
No Picture
News

Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

LA JOLLA, Calif.: LA JOLLA, Calif., Aug. 9, 2021 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the second quarter and six months ended June 30, 2021 and highlighted… Click here to view original post… […]

No Picture
News

Halozyme Reports Second Quarter 2021 Results

SAN DIEGO: SAN DIEGO, Aug. 9, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook. "Our excellent start to 2021 continued in the second quarter with strong quarterly… Click here to view original post… […]

No Picture
News

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

SAN DIEGO–(BUSINESS WIRE)—- $ARCT #ClinicalTrial–Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress Click here to view original post… […]